Penn spin­out preps for hu­man stud­ies of a new-mod­el CAAR, aim­ing at a one-time cure for au­toim­mune dis­eases

Michael Milone learned about en­gi­neer­ing T cells for can­cer at the bench of the mas­ter, work­ing as a post doc in Carl June’s lab at the Uni­ver­si­ty of Penn­syl­va­nia from 2004 to 2007. He went on to play a key role in the sci­en­tif­ic lead­er­ship team de­vel­op­ing No­var­tis’ break­through CAR-T drug Kym­ri­ah at Penn. And now, at the head of his own team of trans­la­tion­al re­searchers, he and Penn’s Aimee Payne and Steven Nicht­berg­er are co-found­ing a biotech that will take what they’ve learned about T cell en­gi­neer­ing in­to au­toim­mune dis­eases, in search of a break­through, once-and-done ap­proach.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER